Drug Profile

Research programme: psychedelic-based neurological therapeutics - Psilera

Latest Information Update: 26 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Psilera
Class Antidepressants; Anxiolytics; Drug withdrawal therapies; Mood stabilisers
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Alcoholism; Anxiety disorders; Depressive disorders; Neurodegenerative disorders

Most Recent Events

04 Apr 2023 Pharmacodynamics data from a preclinical studies in depressive disorders, anxiety, alcohol related-disorders and neurodegenerative disorders released by Psilera
30 Mar 2023 Psilera has patents pending for psychedelic-based neurological therapeutics
30 Mar 2023 Preclinical trials in Alcoholism in USA (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com